Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic Strategies
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 20 January 2026 | Viewed by 2156
Special Issue Editor
Special Issue Information
Dear Colleagues,
Understanding the genomic landscapes of different subtypes of Chronic Lymphocytic Leukemia (CLL) is crucial for improving treatment, identifying predictive indicators, understanding resistance mechanisms, conducting clinical trials, and developing biomarkers. This knowledge helps develop personalized therapies, predict disease progression, and develop strategies to address or prevent resistance to therapies. A deep understanding of the genomic landscape is essential for precision medicine, patient outcomes, and innovative research.
This Special Issue focuses on recent studies that aim to highlight the latest research on the genomic landscapes in CLL. These studies should provide valuable insights that have paved the way for targeted therapies, personalized treatment plans, risk stratification, continuous disease progression monitoring, clinical trials, and biomarker development. These insights allow for the creation of drugs that can target specific genetic mutations, improving treatment effectiveness and reducing side effects. Genomic profiling is also helpful in monitoring disease progression, allowing for timely adjustments in treatment. In general, genomic knowledge greatly improves personalized treatment strategies for patients with CLL.
Dr. Tang Her Jaing
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chronic lymphocytic leukemia
- genomic landscapes
- precision medicine
- clinical trials
- biomarker
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
